| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Epub ahead of print
Jeong, Rim, Yoo, Cho, Chie, Ahn, Lee, and on behalf of Korean Oligometastasis Working Group, Korean Cancer Association: The Clinical Efficacy of Colorectal Cancer Patients with Pulmonary Oligometastases by Sterotactic Body Ablative Radiotherapy: A Meta-Analysis



There is increasing interest in the efficacy of stereotactic ablative radiotherapy (SABR) for treating colorectal cancer (CRC) patients with oligometastases (OM), recently. The purpose of this meta-analysis was to evaluate local control (LC), progression-free survival (PFS), and overall survival (OS) of CRC patients with pulmonary OM treated with SABR and toxicities.

Materials and Methods

Studies that reported SABR for CRC patients with pulmonary OM were searched from MEDLINE and Embase. Treatment outcomes including LC, PFS, OS, and toxicities of grade 3 or higher were assessed.


A total of 19 studies with 1,668 patients were chosen for this meta-analysis. Pooled 1-, 2-, and 3-year LC rates were 83.1%, 69.3%, and 63.9%, respectively. PFS rates were 44.8%, 26.5%, and 21.5% at 1, 2, and 3 years, respectively. OS rates at 1-, 2-, and 3-year were 87.5%, 69.9%, and 60.5%, respectively. The toxicity rate of grade 3 or higher was 3.6%. The effect of dose escalation was meta-analyzed using available studies.


Application of SABR to CRC patients with pulmonary OM achieved modest local control with acceptable toxicity according to the present meta-analysis. Further studies establishing the clinical efficacy of SABR are guaranteed.


According to the traditional oncologic concept, local treatments for metastatic disease have very limited efficacy. Hellman and Weichselbaum first proposed the concept of “oligometastasis” in 1995, which was defined as “the intermediate status between localized and widely disseminated metastatic status” [1]. These authors later advocated the role of metastasis-directed local therapy (MDLT) based on two famous large-scale retrospective studies [2-4]. Afterwards, oncologic benefits of MDLT for oligometastatic lung cancer and prostate cancer were demonstrated by several recent randomized trials [5-7].
Approximately half of colorectal cancer (CRC) patients eventually experience metastasis to other organs [8,9], with the lung being the second most frequent metastatic site [10-12]. Since a large number of CRC patients develop distant metastasis, there is growing interest in the effectiveness of MDLT among clinicians. The first randomized trial using radiofrequency ablation for CRC patients with liver metastases, EORTC-NCRI CCSG-ALM 40004, established the role of MDLT in combination with systemic therapy [13]. The PulMiCC trial, a randomized trial that was stopped due to recruitment difficulties, failed to demonstrate the efficacy of pulmonary metastasectomy over active surveillance, thus emphasizing the limitations of surgery alone and underscoring the potential of other local treatment modality like stereotactic body ablative radiotherapy (SABR) [14]. A recent study suggested the timely performing MDLT including surgery and SABR in addition to systemic therapy could improve overall survival in CRC patients with pulmonary metastases [15]. Moreover, administration of aggressive MDLT, such as repeat SABR, might be associated with improved survival in patients with specific disease-progression patterns [16].
Although surgical resection is preferred in patients with resectable pulmonary metastatic disease [17,18], not all patients could undergo surgery due to patients’ medical comorbidities or disease status. Furthermore, probable complications associated with anesthesia and/or surgical procedures could be burdensome for these patients. With advancement of radiation therapy (RT) technologies, precise and focal delivery of high dose radiation to the target has become possible. SABR is one of the representative examples of modern RT technique that can deliver ablative high dose precisely to targets within a short period of time by applying hypofractionation. By virtue of high local tumor control rate at low level toxicity risk, SABR has emerged as an alternative local treatment option for oligometastases (OM) patients who are unable or unwilling to undergo surgery [19,20]. Favorable clinical outcomes have been reported in several studies, and there has been a recent increase of interest for the efficacy of SABR in treating CRC patients with pulmonary OM.
In CRC patients, pulmonary metastasis is one of the most common patterns of distant metastasis, and it could be detrimental to the prognosis of the patients [11]. However, if appropriate treatments for lung metastases are conducted, there is a possibility to improve the prognosis for CRC patients with pulmonary OM [12]. While there is general agreement that systemic therapy constitutes the standard of treatment for CRC patients with pulmonary OM, the current National Comprehensive Cancer Network guidelines suggest surgical resection or ablative interventions as the preferred option of MDLT for patients with amendable to cure [21]. However, there is no clear consensus in regard to the role of SABR in pulmonary OM. In this context, the purpose of this systematic review and meta-analysis was to investigate clinical efficacy of SABR in treating CRC patients with pulmonary OM and to provide integrated information for future reasonable decision-making by oncologists.

Materials and Methods

1. Information sources and searching strategy

This study was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement, which provided guidelines for reporting systematic reviews and meta-analyses. Methods were carefully planned and executed to ensure reliability and validity of findings [22]. To identify relevant studies, electronic databases were searched using a combination of keywords and Medical Subject Headings (MeSH) terms. Search terms were selected based on their relevance to research questions. They included terms related to primary cancer site (colorectal, colon, sigmoid, rectal, cancer, carcinoma, tumor, neoplasm), metastatic site (lung, pulmonary, metastasis), and treatment (stereotactic body radiotherapy, stereotactic radiotherapy, stereotactic ablative radiotherapy, radiosurgery, stereotactic radiosurgery, stereotactic body radiation therapy). Studies published from June 2012 to June 2022 were searched from online databases of MEDLINE and Embase using selected terms. Original articles with information about human or clinical trials and written in English were chosen. Case reports, literature review, editorial, and only abstracts were excluded from this analysis.

2. Data items and collection process

The primary endpoint of this study was overall survival (OS). Secondary endpoints included progression-free survival (PFS) and local control (LC). We used a pre-standardized sheet to acquire the following data from studies: general information including author name, year of publication, affiliation, and design of studies; clinical information including number of patient numbers, definition of OM (e.g., up to 3 or 5 metastatic foci), age, gender, tumor size, and radiation dose; treatment outcomes including rate of OS, LC, PFS, and complication of grade 3 or higher. Data acquisition and assessment were performed by two researchers (J.U.J., C.H.R.).

3. Quality assessment

Considering that majority of available literatures were observational studies, we used the Newcastle-Ottawa scale (NOS) for quality assessment [23]. Studies were classified as high-quality studies if their NOS scores were 7-9. Those with NOS scores of 5-6 were considered as medium-quality studies and those with NOS scores of 4 or less were classified as low-quality studies. Low-quality studies were excluded from this meta-analysis after reevaluation and agreement among authors.

4. Statistical analyses

The effect measure was pooled percentile of retrieved endpoints of interest (LC, PFS, and OS). Considering possible heterogeneity in clinical regards among institutions and recommendation of Cochrane Handbook regarding pooled analysis of non-randomized studies, the random effects model was used for pooled analyses. Cochrane Q test and I2 test were performed for heterogeneity evaluation and I2 statistic of 25%, 50%, or 75% indicated a low, moderate, or high heterogeneity, respectively [24,25]. Publication bias assessment was performed using visual funnel plot assessment and quantitative Egger’s test [26]. Two-tailed p-value of < 0.1 indicated a possible publication bias. The Duval and Tweedie’s trim and fill was performed as sensitivity test for analyses with possible publication bias [27]. A comparative analysis was conducted using selected studies in which LC and OS were clearly described according to the radiation dose. All statistical analyses were performed using Comprehensive Meta-Analysis ver. 3 (Biostat Inc., Englewood, NJ).


1. Study selection and characteristics

We identified 1,958 studies from the two databases: 1,198 from Embase and 760 from MEDLINE. Among these, 135 duplicated studies were removed. Remained 1,823 studies were screened and 1,781 were excluded. A total of 42 studies were selected to conduct full text review. After an eligibility evaluation process, 31 studies were excluded. Additional eight studies were identified through website search and citation tracking. They were included in the current study. Finally, a total of 19 studies with 1,668 patients were used for this meta-analysis (Fig. 1) [28-46].
Most studies included in the present analysis were retrospective studies except for two. Fourteen studies used the definition of OM by the number of lesions, while five used the maximum number of lesions. The median biologically effective dose (BED) of SABR with an α/β ratio of 10 (BED10) ranged from 93.6 Gy to 180 Gy (Table 1). Clinical outcomes from each study are shown in Table 2. Among a total of 19 studies, 16, 10, and 12 studies reported LC, PFS, and OS, respectively. The assessment for LC was based on metastatic lesions except for two studies [34,42].

2. Quality assessment

All selected studies were categorized to have a medium quality. Therefore, no study was excluded from subsequent pooled analyses. Detail sheet of scoring and reason of scoring are shown in S1 Table.

3. Synthesized results

Pooled rates of LC at 1-, 2-, and 3-year were 83.1% (95% confidence interval [CI], 79.0% to 86.5%), 69.3% (95% CI, 63.3% to 74.7%), and 63.9% (95% CI, 56.3% to 70.8%), respectively (Fig. 2A). Pooled OS rates at 1-, 2-, and 3-year were 87.5% (95% CI, 82.6% to 91.1%), 69.9% (95% CI, 61.4% to 77.3%), and 60.5% (95% CI, 56.0% to 64.8%), respectively (Fig. 2B). Pooled PFS rates at 1-, 2-, and 3-year were 44.8% (95% CI, 35.1% to 54.8%), 26.5% (95% CI, 19.7% to 34.7%), and 21.5% (95% CI, 16.1% to 28.1%), respectively (Fig. 2C). Treatment-related toxicities were reported in 13 studies. Pooled complication rate of grade 3 or higher was 3.6% (95% CI, 1.9% to 6.8%) (S2 Fig.). Majority of reported grade ≥ 3 toxicities were radiation pneumonitis, while Sheikh et al. [46] reported three (2.3%) cases of bile duct stenosis. Heterogeneity assessment showed moderate to high heterogeneity in most of the pooled analyses. Synthesized results are shown in Table 3.

4. Publication bias

The publication bias assessment was performed for LC, OS, PFS, and grade ≥ 3 complication pooled analyses. Possible publication bias was not found in pooled analyses of LC, OS, or PFS. However, it was found in pooled analyses of treatment complication (Egger’s p=0.026). The Duval and Tweedie’s trim and fill was performed for pooled analysis of complication rate, which yieded an adjusted value of 5.1%. Visual funnel plots including Egger’s p-values are shown in S3 Fig.

5. Radiation dose assessment among studies

Most studies included in this meta-analysis evaluated clinical outcomes based on radiation dose. Seven studies specifically examined the effect of radiation dose on clinical outcomes (Table 4). In five out of seven studies, dose escalation was found to be a favorable factor for clinical outcomes. Four studies reported that dose escalation was a good prognostic factor for LC, while three studies found that it was beneficial for OS.
To further investigate the impact of SABR dose on treatment outcomes, we conducted a meta-analysis using data from five studies [31,35,36,42,45] on LC and three studies [36,42,45] on OS (Table 5). The analysis showed that the higher radiation-dose group (more than 100 Gy in BED10) had better LC than the lower radiation-dose group (odds ratio [OR], 0.258; 95% CI, 0.155 to 0.430; p < 0.001) (Fig. 3A). Furthermore, we found that dose escalation could lead to improved OS (OR, 0.597; 95% CI, 0.361 to 0.986; p=0.044) (Fig. 3B).


In the current meta-analysis, pooled LC, PFS, and OS rates were 69.3%, 26.5%, 69.9% at 2-year and 63.9%, 21.5%, and 60.5% at 3-year, respectively. These results were comparable to those following pulmonary metastasectomy, with 3-year survival rates of 58% and 67.7% reported in the United States and Korea, respectively [47,48]. One study used in present analysis showed that the treatment result of SABR were not inferior to those of surgery for CRC patients with pulmonary OM [33]. For patients who are unable or unwilling to undergo surgery, SABR could be an alternative option for MDLT. This meta-analysis demonstrates that SABR could be a feasible option for CRC patients with pulmonary OM.
Therapeutic efficacy of SABR in treating pulmonary OM has been reported to be non-inferior to that of surgical resection, while SABR could lead to less frequent severe complications than surgical resection [33]. Major toxicities associated with SABR for pulmonary lesions typically include pneumonitis, chest wall pain, and neuropathy. Reported rates of toxicity vary among studies. They might have been influenced by factors such as tumor burden, location, and radiation dose [49]. While two studies reported severe toxicity rates around 10%, the majority of studies, including those included in this meta-analysis, reported no severe toxicities greater than grade 3.
There is considerable heterogeneity in the clinical characteristics among the patients included in these analyses. The number of metastases varied from 1 to 5 and the presence of extrapulmonary metastases differed among included studies. Chemotherapy before SABR was administered to the majority of patients, ranging from 58% to over 90% in each study except one. SABR was performed using either a linear accelerator or CyberKnife and it was ensured that either the percent volume receiving at least 95% of the prescription dose was over 95% or the 60%-90% isodose line of the prescribed dose covered the planning target volume. There are several points of consideration for determining the optimal dose of SABR based on the heterogeneity in clinical settings. First, various dosimetric parameters should be considered, not only prescribed radiation dose but also maximum and average dose for targets in the era of advanced radiotherapy technologies such as intensity-modulated and volumetricmodulated arc therapies, which enable more accurate dose distribution [50]. The presence of a hot spot within the tumor volume might have the potential to increase LC. Several studies included in this research have made efforts to ensure the hot dose within the tumor volume such as at least 120% of the prescription dose in gross target volume [29] or > 105% of the prescription dose within planning target volume [30]. Second, the radiobiological parameter is differed according to the primary histology and metastatic organ, and it should be taken into consideration to determine the optimal radiation dose [51]. Several studies included in the present analysis reported that colorectal histology showed worse prognosis than other types of primary tumors [29,32]. Although the treatment outcomes of SABR would be varied among CRC patients in the present study, depending on factors such as the primary tumor site (colon or rectum) [36], genetic influences (BRAF or KRAS mutations) [36,41], and metastatic sites (lung, liver, or others) [46]. However, one study reported that there was no difference in local PFS according to the primary site (colon or rectum) or genetic mutation [45]. It is still challenging to evaluate biologic effects on prognosis after SABR. Third, radiation dose to obtain the same tumor control probability may differ due to clinical factors such as tumor extent. Several studies included in this analysis also showed various prescribed doses depending on tumor size and location, and surrounding organs at risk [28,33,34,36,37,42,45,46]. It was observed that tumors with small size [28,33,34,37,45,46], small number of metastatic lesions [34,36], and peripheral tumors [34,36,37,40] tended to have an increased BED10, ranging from 120 to 180 Gy, compared to others, ranging from 75 Gy to 100 Gy. For these reasons, the ideal dose of SABR remains undetermined, but clinical efforts are needed to find the appropriate dose for each metastatic CRC patients.
Delivering optimal radiation dose by SABR could be essential to achieve tumor control probability. The appropriate dose of SABR is a crucial factor in predicting clinical outcomes. Several studies have previously shown that higher BED10 is associated with reduced local recurrence [35,42,43,45]. One study has found that local recurrence is higher in patients treated with a BED10 < 100 Gy than in those receiving > 100 Gy [29]. Other studies have reported a significant positive correlation between BED10 and LC, with cut-offs ranging from 75 Gy to 112.5 Gy [39]. Increasing the BED10 to higher than 100 Gy has been shown to be able to improve local tumor response, which could lead to an improved OS rate. For patients with pulmonary OM, the median survival time longer than 4 years could be expected following BED10 > 100 Gy, whereas it could be shorter than 3 years following BED10 < 100 Gy [42,45]. It seems appropriate administering SABR with BED10 ≥ 100 Gy for pulmonary metastatic lesions.
When applicating SABR to metastatic CRC patients, several clinical scenarios should be taken into consideration. The inherent tumor characteristics, such as metastatic tumor burden, which includes the number of metastatic lesions and tumor volume, could affect the prognosis for CRC patients with pulmonary OM. In present analysis, cases of small tumor burden in the lung showed a trend of higher prescribed BED10, ranging from 112.5 to 180 Gy, compared to those of large tumor burden, ranging from 76 to 87.5 Gy, and metastatic tumor burden was determined to be an independent factor for prognosis [29,36,38-40,42,45,46]. The prognosis might be different regarding to timing the occurrence of metastases. Metachronous onset of OM was a favorable factor for survival in a study to estimate the prognosis of oligometastatic patients [52,53]. In CRC patients with pulmonary OM, the 3-year survival rate was 73.5% with disease-free interval more than 2 years, while it was 65% in patients with disease-free interval less than 2 years [54]. In present analysis, metachronous disease showed better prognosis in LC [40] and PFS [34,38] compared to synchronous disease. Patients with slow-growing disease like metachronous tumors would benefit more from SABR and administration of subsequent treatments would be delayed [29]. A significantly large portion of metastases with CRC patients received chemotherapy prior to SABR and chemotherapy before SABR would influence tumor control rate [55]. In the present analysis, administration of chemotherapy before SABR was reported to have no effect on treatment outcomes in some studies [41,45], but many other studies showed a negative effect on prognosis [38,42-44,46]. Interestingly, one study demonstrated that adjuvant chemotherapy after SABR was a favorable factor for LC [35]. Macroscopic tumor shrinkage after chemotherapy could result in a marginal miss of microscopic disease, and surviving tumor cells after chemotherapy are likely to be more radioresistant.
However, our study has several limitations, which should be taken into consideration when interpreting our findings. First, most studies included in our meta-analysis were retrospective in nature and some studies had a small sample size, which might have led to a selection bias. Additionally, there were significant differences in treatments (chemotherapy or surgery) delivered to patients prior to SABR. It is difficult to evaluate the efficacy of SABR exactly unless factors like tumor size, treatment timing or sequence (i.e., pretreatment chemotherapy and SABR), and appropriate radiation dose is adequately controlled. Therefore, randomized trials are needed to identify eligible patients and determine the optimal SABR dose schedule in a clinical setting.
In conclusion, our meta-analysis demonstrates the potential role of SABR in treating CRC patients with pulmonary OM. Our study supports the use of SABR as a viable option for local tumor control. Several studies have shown the optimal BED10 of SABR is more than 100 Gy, but it still requires efforts to figure out ideal dose via clinical trials. Nevertheless, SABR could be a valid option in treating pulmonary OM for ineligible patients to undergo metastasectomy. Further studies with a larger sample size and randomized study design are highly desired to confirm our findings and determine the optimal treatment strategies.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).


Author Contributions

Conceived and designed the analysis: Ahn YC, Lee JH.

Collected the data: Jeong JU, Rim CH, Yoo GS, Cho WK, Chie EK, Ahn YC, Lee JH.

Contributed data or analysis tools: Yoo GS, Cho WK, Chie EK, Lee JH.

Performed the analysis: Jeong JU, Rim CH, Lee JH.

Wrote the paper: Jeong JU, Rim CH, Lee JH.

Conflicts of Interest

Yong Chan Ahn, the editor-in-chief of the Cancer Research and Treatment, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.

Fig. 1.
Flow chart showing the idendification of relevant studies.
Fig. 2.
Pooled estimation of local control (LC) (A), overall survival (OS) (B), and progression-free survival (PFS) (C) after stereotactic radiotherapy [28-46]. CI, confidence interval.
Fig. 3.
Pooled estimation of local control (A) and overall survival (B) according to the radiation dose [31,35,36,42,45]. CI, confidence interval; HD, high dose with ≥ 100 Gy in biological effective dose; LD, low dose with < 100 Gy in biological effective dose.
Table 1.
General information of included studies
Author (year) Study design Definition of oligometastasis No. of patients (lesions) No. patients with extapulmonary lesion Median age (yr) Male (%) Median tumor size (cm) No. of patients with previous chemotherapy Dose prescription SABR modality Median BED10 (Gy)
Comito (2014) [28] P 3 40 (60) 0 NA NA NA NA V98% ≥ 98% for CTV and V95% ≥ 95% for PTV; 20 Gy×3 fx, 12 Gy×4 fx Linac 105.6
Binkley (2015) [29] R NA 26 (26) NA NA NA NA NA in GTV V95% ≥ 95% for PTV and Dmax ≥ 120% NA NA
Carvajal (2015) [30] P 1 13 (13) 0 60 69.3 1 NA 60%-90% isodose line covering PTV; 12.5 Gy×4 fx, 18 Gy×3 fx, 34 Gy×1 fx, 7.5 Gy×8 fx Linac 149.6
Jung (2015) [31] R 3 50 (79) 0 65 NA NA (1.5 mL) 32 85%-90% isodoseline covering PTV Linac 105.6
Aoki (2016) [32] R 3 13 (15) NA NA NA NA 0 10 Gy×5 fx Linac (3D-CRT) NA
Filippi (2016) [33] R 5 28 (43) NA 72 50 1.15 NA 80% Isodoseline covering PTV Linac (3D-CRT or VMAT) 93.6
Agolli (2017) [34] R 4 44 (69) 11 68 73 1.4 26 23 Gy×1 fx for multiple lesions, 30 Gy×1 fx for peripheral or small lesions (< 30 mL), 15 Gy×3 fx for central or large lesions (≥ 30 mL) Linac 120
Jingu (2017) [35] R NA 93 (104) NA 69 64.5 1.5 NA V95% ≥ 95% for PTV NA 105.6
Kinj (2017) [36] R 5 53 (87) NA 69 66 1.6 NA 25 Gy×1 fx for multiple lesions (> 3), 20 Gy×3 fx for peripheral lesions, 10-15 Gy×5 fx for central lesions CK 180
Pasqualetti (2017) [37] R 3 33 (56) NA 67 75.7 NA NA 24-26 Gy×1 fx, 9-14 Gy×3 fx Linac 93.6
Qiu (2018) [38] R NA 65 (144) 23 NA 56.9 NA 45 80% Isodoseline covering PTV; 5 Gy×10 fx, 10 Gy×5 fx Linac NA
Dell’Acqua (2019) [39] R 5 54 (97) NA NA NA NA NA 70%-80% Isodoseline covering PTV for CK; V95% ≥ 95% for PTV for Linac CK or Linac NA
Kalinauskaite (2020) [40] R NA 17 (NA) NA NA NA NA NA 70% Isodoseline covering PTV and Dmax ≤ 100% for CK; 80% isodoseline covering PTV and Dmax ≤ 110% for Linac CK or Linac NA
Nicosia (2020) [41] R 5 38 (107) NA 75 NA 1.4 22 V95% ≥ 95% and Dmax ≤ 107% for PTV Linac (VMAT) 96
Sharma (2020) [42] R 5 118 (NA) 69 NA 65.2 NA 73 70%-90% isodose line covering PTV; peripheral lesions: 17 Gy×3 fx or 20 Gy×3 fx or 30 Gy×1 fx for peripheral lesions, 5 Gy×10-12 fx or 7 Gy×7 fx or 8 Gy×6-7 fx for central lesions CK NA
Yamamoto (2020) [43] R 5 330 (370) NA 73 61.2 NA 148 NA NA 115.3
Benson (2021) [44] R NA 18 (28) NA 58 33 NA (1 mL) NA (26 lesions) NA CK or Linac 113
Nicosia (2022) [45] R 5 620 (1,090) NA 70 (mean) 36 NA (104 mL) 383 NA NA 105
Sheikh (2022) [46] R 5 133 (239) NA NA NA NA NA NA NA NA

BED10, biologically effective dose with α/β ratio of 10; CK, CyberKnife; CTV, clinical target volume; Dmax, maximum point dose; fx, fraction; GTV, gross target volume; Linac, linear accelerator; NA, not assessable; P, prospective; PTV, planning target volume; R, retrospective; SABR, stereotactic ablative radiotherapy; V95%, the percent volume that received at least 95% of the prescription dose; VMAT, volumetric modulated arc therapy; 3D-CRT, three-dimensional conformal radiotherapy.

Table 2.
Clinical outcome of included studies
Author (year) Median F/U (mo) No. of patients No. of lesions LC (%)
Median PFS (mo) PFS (%)
Median OS (mo) OS (%)
Toxicity (≥ grade 3)
1-yr 2-yr 3-yr 5-yr 1-yr 2-yr 3-yr 1-yr 2-yr 3-yr
Comito (2014) [28] NA 40 60 85 75 70 NA NA NA NA NA NA 87 68 58 0
Binkley (2015) [29] NA 26 26 74.5 57.8 NA NA NA NA NA NA NA NA NA NA NA
Carvajal (2015) [30] 9.16 (2.2-45.6) 13 13 92.3 92.3 92.3 NA NA 45.8 22.9 22.9 NA 92.3 92.3 66.7 0
Jung (2015) [31] 42.8 (11.0-104.1) 50 79 88.7 74 70.6 NA NA 38 26 24 NA 95 75 64 0
Aoki (2016) [32] NA 13 15 100 67.6 47.6 NA NA 75 44 0 NA NA NA 60.6 0
Filippi (2016) [33] 27 (16.1-71.7) 28 43 NA NA NA NA NA 53.6 17.9 NA NA 89 77 NA 14.4% (pneumonitis)
Agolli (2017) [34] 36 44 69 72 68 66 NA 10 40.7 20.3 16.2 Not reached 82.8 67.7 50.8 0
Jingu (2017) [35] 28 93 104 87.3 72 65.2 56.2 NA NA NA NA NA 88.7 61.3 55.9 2.2% (pneumonitis)
Kinj (2017) [36] 33 (4-85) 53 87 79.8 78.2 75 70 NA 29.2 14.6 7.5 NA 83.8 69.3 75 0
Pasqualetti (2017) [37] 22.8 (1.3-45.7) 33 56 62 30 22 NA 13 NA NA NA NA NA NA NA 0
Qiu (2018) [38] NA 64 144 NA NA NA NA 5.7 23.5 10.1 NA 20.3 77.8 42.8 NA NA
Dell’Acqua (2019) [39] NA 54 97 78 75 45 NA NA NA NA NA NA NA NA NA 0
Kalinauskaite (2020) [40] NA 17 NA 59 46 NA NA NA NA NA NA NA NA NA NA NA
Nicosia (2020) [41] 28 38 107 NA NA NA NA 7 62.5 53.4 NA 39.5 76.3 71.1 NA NA
Sharma (2020) [42] 31 118 NA 90 83 81 77 12.1 NA 38 29 39.2 89 69 55 6% (pneumonitis, chest pain)
Yamamoto (2020) [43] 25 (0.1-121.3) 330 370 86.1 65.3 64.9 NA 12.6 52.6 28.7 24.9 51.5 94.4 82.7 63.4 2% (pneumonitis)
Benson (2021) [44] NA 18 28 86.3 NA NA NA NA NA NA NA NA NA NA NA NA
Nicosia (2022) [45] 26 620 1,090 86.1 75.4 72.3 NA 11.4 NA NA NA NA NA NA NA NA
Sheikh (2022) [46] NA 133 239 88 70 60 55 NA NA NA NA NA NA NA NA 11.3% (pneumonitis, bile duct stenosis)

F/U, follow-up; LC, local control; NA, not assessable; OS, overall survival; PFS, progression-free survival.

Table 3.
Pooled results of clinical endpoints
No. of studies No. of patients Heterogeneity, p-value I2 (%) Heterogeneity assessment Effect size (95% CI) Egger’s test, p-value
Local control
 1-Year 15 2,354 < 0.001 71.7 Moderate to high 83.1 (79.0-86.5) 0.464
 2-Year 14 2,326 < 0.001 82.7 High 69.3 (63.3-74.7)
 3-Year 12 2,271 < 0.001 88.4 High 63.9 (56.3-70.8)
Overall survival
 1-Year 11 871 0.002 63.4 Moderate to high 87.5 (82.6-91.1) 0.744
 2-Year 11 871 < 0.001 80.5 High 69.9 (61.4-77.3)
 3-Year 9 754 0.251 21.6 Low 60.5 (56.0-64.8)
Progression-free survival
 1-Year 9 633 < 0.001 76.1 High 44.8 (35.1-54.8) 0.554
 2-Year 10 751 < 0.001 73.8 Moderate to high 26.5 (19.7-34.7)
 3-Year 7 621 0.057 50.9 Moderate 21.5 (16.1-28.1)
Toxicity (grade 3 or higher) 13 1,002 0.003 59.4 Moderate to high 3.6 (1.9-6.8) 0.026

CI, confidence interval.

Table 4.
Clinical outcome according to the BED10 of stereotactic radiotherapy for colorectal patients with pulmonary oligometastases
Author (year) Local control Progression-free survival Overall survival
Jung (2015) [31] < 150 Gy vs. ≥ 150 Gy for 3-year: 84% vs. 64.6% (p=0.14) NA < 150 Gy vs. ≥ 150 Gy for 3-year: 54.5% vs. 82.4% (p=0.12)
Jingu (2017) [35] *< 100 Gy vs. ≥ 100 Gy for 2-year: 64.5% vs. 95.5% (p=0.011) NA NA
Kinj (2017) [36] < 180 Gy vs. ≥ 180 Gy for 2-year: 70.4% vs. 81.6% (p=0.4) NA < 180 Gy vs. ≥ 180 Gy for 2-year: 36.5% vs. 74.9% (p=0.055)
Qiu (2018) [38] ≥ 80 Gy: 0.14 for HR (p=0.05) NA ≥ 80 Gy: 0.48 for HR (p=0.16)
Sharma (2020) [42] *< 100 Gy vs. ≥ 100 Gy for 2-year: 62% vs. 87% (p < 0.001) NA *< 100 Gy vs. ≥ 100 Gy for median months: 30.8 vs. 48.8 (p=0.027)
Yamamoto (2020) [43] * < 115 Gy vs. ≥ 115 Gy for 3-year: 56.5% vs. 70.3% (p=0.06) *< 115 Gy vs. ≥ 115 Gy for median months: 11.7 vs. 12.7 (p=0.06) *< 115 Gy vs. ≥ 115 Gy for median months: 41.0 vs. 84.0 (p=0.01)
Nicosia (2022) [45] *< 100 Gy vs. 100-125 Gy vs. ≥ 125 Gy for 2-year: 76.1% vs. 70.6% vs. 94% (p < 0.001) NA *< 100 Gy vs. 100-125 Gy vs. ≥ 125 Gy for median months: 35.5 vs. 42 vs. 58.5 (p=0.0045)

BED10, biologically effective dose with α/β ratio of 10; HR, hazard ratio; NA, not assessable. *It was proven as an independent factor in the multivariate analysis.

Table 5.
Outcome comparison according to the radiation dose
No. of studies No. of patients Heterogeneity, p-value I2 (%) Heterogeneity assessment Effect size (95% CI) p-value
Local control
 Overall 5 1,365 0.322 14.50 Low OR 0.258 (0.155-0.430) < 0.001
 LD arm 5 847 0.465 ~0 Very low 2-yr LC 71.7% (68.9-74.4)
 HD arm 5 326 0.085 51.20 Moderate 2-yr LC 88.8% (82.0-93.2)
Overall survival
 Overall 3 781 0.298 17.40 Low OR 0.597 (0.361-0.986) 0.044
 LD arm 3 505 0.033 70.60 Moderate to high 2-yr OS 63.1% (45.8-77.6)
 HD arm 3 233 0.535 ~0 Very low 2-yr OS 75.6% (69.6-80.7)

CI, confidence interval; HD, high dose with ≥ 100 Gy in biological effective dose; LC, local control; LD, low dose with < 100 Gy in biological effective dose; OR, odds ratio; OS, overall survival.


1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
crossref pmid
2. Hughes KS, Rosenstein RB, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of longterm survivors. Dis Colon Rectum. 1988;31:1–4.
pmid pmc
3. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254–62.
crossref pmid
4. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.
crossref pmid pdf
5. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local consolidative therapy Vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37:1558–65.
crossref pmid pmc
6. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4:e173501
crossref pmid pmc
7. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.
pmid pmc
8. Biasco G, Derenzini E, Grazi G, Ercolani G, Ravaioli M, Pantaleo MA, et al. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev. 2006;32:214–28.
crossref pmid
9. Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42:2212–21.
crossref pmid
10. Grossmann I, Avenarius JK, Mastboom WJ, Klaase JM. Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure. Ann Surg Oncol. 2010;17:2045–50.
crossref pmid pmc
11. Qiu M, Hu J, Yang D, Cosgrove DP, Xu R. Pattern of distant metastases in colorectal cancer: a SEER based study. Oncotarget. 2015;6:38658–66.
crossref pmid pmc
12. Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol. 2015;21:11767–76.
crossref pmid pmc
13. Ruers T, Punt C, Van Coevorden F, Pierie J, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619–26.
crossref pmid pmc
14. Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, et al. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials. 2019;20:718.
crossref pmid pmc pdf
15. Lee BM, Chang JS, Koom WS, Byun HK, Kim HS, Beom SH, et al. Importance of local ablative therapies for lung metastases in patients with colorectal cancer. Ann Surg. 2023;278:e173
crossref pmid
16. Willmann J, Adilovic S, Vlaskou Badra E, Christ SM, Ahmadsei M, Tanadini-Lang S, et al. Repeat stereotactic body radiotherapy for oligometastatic disease. Radiother Oncol. 2023;184:109671.
crossref pmid
17. Onaitis MW, Petersen RP, Haney JC, Saltz L, Park B, Flores R, et al. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg. 2009;87:1684–8.
crossref pmid
18. Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Colorectal Dis. 2007;22:699–704.
crossref pmid pdf
19. Okunieff P, Petersen AL, Philip A, Milano MT, Katz AW, Boros L, et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol. 2006;45:808–17.
crossref pmid
20. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.
crossref pmid
21. NCCN Clinical Practice Guidelines in Oncology. Colon cancer version 4.2023 [Internet]. Plymouth Meeing, PA: National Comprehensive Cancer Network; c2023 [cited 2023 Nov 15]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428

22. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
crossref pmid
23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
crossref pmid pdf
24. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.
25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
crossref pmid
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
crossref pmid pmc
27. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics. 2000;56:455–63.
crossref pmid
28. Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarria P, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014;14:619.
crossref pmid pmc pdf
29. Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le QT, Maxim PG, et al. Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:1044–52.
crossref pmid
30. Carvajal C, Navarro-Martin A, Cacicedo J, Ramos R, Guedea F. Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results. J BUON. 2015;20:158–65.
31. Jung J, Song SY, Kim JH, Yu CS, Kim JC, Kim TW, et al. Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiat Oncol. 2015;10:238.
crossref pmid pmc
32. Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, et al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. J Radiat Res. 2016;57:55–61.
crossref pmid pmc
33. Filippi AR, Guerrera F, Badellino S, Ceccarelli M, Castiglione A, Guarneri A, et al. Exploratory analysis on overall survival after either surgery or stereotactic radiotherapy for lung oligometastases from colorectal cancer. Clin Oncol (R Coll Radiol). 2016;28:505–12.
crossref pmid
34. Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF. Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer. 2017;16:58–64.
crossref pmid
35. Jingu K, Matsuo Y, Onishi H, Yamamoto T, Aoki M, Murakami Y, et al. Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer. Anticancer Res. 2017;37:2709–13.
crossref pmid
36. Kinj R, Bondiau PY, Francois E, Gerard JP, Naghavi AO, Leysalle A, et al. Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy. Clin Colorectal Cancer. 2017;16:e211
crossref pmid
37. Pasqualetti F, Montrone S, Vivaldi C, Zani M, Fedele D, Fornaro L, et al. Stereotactic body radiotherapy in patients with lung oligometastases from colorectal cancer. Anticancer Res. 2017;37:315–9.
crossref pmid
38. Qiu H, Katz AW, Chowdhry AK, Usuki KY, Singh DP, Metcalfe S, et al. Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol. 2018;41:53–8.
39. Dell’Acqua V, Surgo A, Kraja F, Kobiela J, Zerella MA, Spychalski P, et al. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. Clin Exp Metastasis. 2019;36:331–42.
crossref pmid pdf
40. Kalinauskaite GG, Tinhofer II, Kufeld MM, Kluge AA, Grun AA, Budach VV, et al. Radiosurgery and fractionated stereotactic body radiotherapy for patients with lung oligometastases. BMC Cancer. 2020;20:404.
crossref pmid pmc pdf
41. Nicosia L, Cuccia F, Mazzola R, Ricchetti F, Figlia V, Giaj-Levra N, et al. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. Strahlenther Onkol. 2020;196:813–20.
crossref pmid pdf
42. Sharma A, Baker S, Duijm M, Oomen-de Hoop E, Cornelissen R, Verhoef C, et al. Prognostic factors for local control and survival for inoperable pulmonary colorectal oligometastases treated with stereotactic body radiotherapy. Radiother Oncol. 2020;144:23–9.
crossref pmid
43. Yamamoto T, Niibe Y, Matsumoto Y, Onishi H, Aoki M, Nishikawa A, et al. Analyses of local control and survival after stereotactic body radiotherapy for pulmonary oligometastases from colorectal adenocarcinoma. J Radiat Res. 2020;61:935–44.
crossref pmid pmc pdf
44. Benson KRK, Sandhu N, Zhang C, Ko R, Toesca DA, Lee PE, et al. Local recurrence outcomes of colorectal cancer oligometastases treated with stereotactic ablative radiotherapy. Am J Clin Oncol. 2021;44:559–64.
crossref pmid
45. Nicosia L, Franceschini D, Perrone-Congedi F, Casamassima F, Gerardi MA, Rigo M, et al. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. Radiother Oncol. 2022;166:92–9.
46. Sheikh S, Chen H, Sahgal A, Poon I, Erler D, Badellino S, et al. An analysis of a large multi-institutional database reveals important associations between treatment parameters and clinical outcomes for stereotactic body radiotherapy (SBRT) of oligometastatic colorectal cancer. Radiother Oncol. 2022;167:187–94.
crossref pmid
47. Siebenhuner AR, Guller U, Warschkow R. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. BMC Cancer. 2020;20:246.
pmid pmc
48. Yu WS, Bae MK, Choi JK, Hong YK, Park IK. Pulmonary metastasectomy in colorectal cancer: a population-based retrospective cohort study using the Korean National Health Insurance Database. Cancer Res Treat. 2021;53:1104–12.
crossref pmid pmc pdf
49. Kuo HT, Que J, Lin LC, Yang CC, Koay LB, Lin CH. Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e9249
crossref pmid pmc
50. Owen D, Siva S, Salama JK, Daly M, Kruser TJ, Giuliani M. Some like it hot: the value of dose and hot spots in lung stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2023;117:1–5.
crossref pmid
51. Klement RJ. Radiobiological parameters of liver and lung metastases derived from tumor control data of 3719 metastases. Radiother Oncol. 2017;123:218–26.
crossref pmid
52. Van den Begin R, Engels B, Collen C, de Vin T, Defauw A, Dubaere E, et al. The METABANK score: a clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease. Radiother Oncol. 2019;133:113–9.
crossref pmid
53. Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, et al. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol. 2022;168:256–64.
crossref pmid
54. Franzese C, Comito T, Franceschini D, Loi M, Clerici E, Navarria P, et al. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy. J Cancer Res Clin Oncol. 2020;146:1227–34.
crossref pmid pdf
55. Klement RJ, Guckenberger M, Alheid H, Allgauer M, Becker G, Blanck O, et al. Stereotactic body radiotherapy for oligometastatic liver disease: influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017;123:227–33.
crossref pmid
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI